<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Cardiovascular Clinical Reference | COVID-19 Resources for Penn Cardiologists</title>
  <meta name="description" content="Cardiovascular Clinical Reference | COVID-19 Resources for Penn Cardiologists" />
  <meta name="generator" content="bookdown 0.18 and GitBook 2.6.7" />

  <meta property="og:title" content="Cardiovascular Clinical Reference | COVID-19 Resources for Penn Cardiologists" />
  <meta property="og:type" content="book" />
  
  <meta property="og:image" content="images/SARS-CoV-2_without_background.png" />
  
  <meta name="github-repo" content="mglev1n/PennCVM-COVID" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Cardiovascular Clinical Reference | COVID-19 Resources for Penn Cardiologists" />
  
  
  <meta name="twitter:image" content="images/SARS-CoV-2_without_background.png" />

<meta name="author" content="Michael Levin, MD; Yoav Karpenshif, MD; Megan Burke, MD; Frank E. Silvestry MD on behalf of the Penn Cardiovascular Fellowship program" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  <link rel="apple-touch-icon-precomposed" sizes="120x120" href="images/SARS-CoV-2_without_background.png" />
  <link rel="shortcut icon" href="images/SARS-CoV-2_without_background.png" type="image/x-icon" />
<link rel="prev" href="major-cardiovascular-society-resources.html"/>
<link rel="next" href="clinical-trials.html"/>
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />












</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="penn-resources.html"><a href="penn-resources.html"><i class="fa fa-check"></i>Penn Resources</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html"><i class="fa fa-check"></i>Major Cardiovascular Society Resources</a><ul>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#american-college-of-cardiology-acc"><i class="fa fa-check"></i>American College of Cardiology (ACC)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#american-heart-association-aha"><i class="fa fa-check"></i>American Heart Association (AHA)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#european-society-of-cardiology-esc"><i class="fa fa-check"></i>European Society of Cardiology (ESC)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#society-for-cardiovascular-angiography-and-interventions-scai"><i class="fa fa-check"></i>Society for Cardiovascular Angiography and Interventions (SCAI)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#heart-rhythm-society-hrs"><i class="fa fa-check"></i>Heart Rhythm Society (HRS)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#american-society-of-echocardiography-ase"><i class="fa fa-check"></i>American Society of Echocardiography (ASE)</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html"><i class="fa fa-check"></i>Cardiovascular Clinical Reference</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#acute-cardiac-injury"><i class="fa fa-check"></i>Acute Cardiac Injury</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#definition"><i class="fa fa-check"></i>Definition</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#prognostic-implications"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#treatment-considerations"><i class="fa fa-check"></i>Treatment Considerations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#acute-coronary-syndrome"><i class="fa fa-check"></i>Acute Coronary Syndrome</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#definition-1"><i class="fa fa-check"></i>Definition</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence-1"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics-1"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#treatment-considerations-scai-guidelines"><i class="fa fa-check"></i>Treatment Considerations (SCAI Guidelines)</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#stemi"><i class="fa fa-check"></i>STEMI</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#nstemi"><i class="fa fa-check"></i>NSTEMI</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#arrhythmia"><i class="fa fa-check"></i>Arrhythmia</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence-2"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics-2"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#treatment-considerations-1"><i class="fa fa-check"></i>Treatment Considerations</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#atrial-fibrillationflutter"><i class="fa fa-check"></i>Atrial Fibrillation/Flutter</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#ventricular-tachycardia"><i class="fa fa-check"></i>Ventricular Tachycardia</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#myopericarditis"><i class="fa fa-check"></i>Myo/Pericarditis</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence-3"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics-3"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#management"><i class="fa fa-check"></i>Management</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#thromboembolic-diseasecoagulopathy"><i class="fa fa-check"></i>Thromboembolic Disease/Coagulopathy</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence-4"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics-4"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#prognostic-implications-1"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#treatment-considerations-2"><i class="fa fa-check"></i>Treatment Considerations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release"><i class="fa fa-check"></i>Secondary Hemophagocytic Lymphohistiocytosis/Cytokine Release</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#definition-2"><i class="fa fa-check"></i>Definition</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#clinical-presentation"><i class="fa fa-check"></i>Clinical Presentation</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence-5"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics-5"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#prognostic-implications-2"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#treatment-considerations-3"><i class="fa fa-check"></i>Treatment Considerations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#cardiomyopathyheart-failurecardiogenic-shock"><i class="fa fa-check"></i>Cardiomyopathy/Heart Failure/Cardiogenic Shock</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#incidence-6"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#diagnostics-6"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#prognostic-implications-3"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#management-1"><i class="fa fa-check"></i>Management</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#stablechronic"><i class="fa fa-check"></i>Stable/Chronic</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#unstablecardiogenic-shock"><i class="fa fa-check"></i>Unstable/Cardiogenic Shock</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#medication-considerations"><i class="fa fa-check"></i>Medication Considerations</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#acearbarni"><i class="fa fa-check"></i>ACE/ARB/ARNI</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#pathophysiology"><i class="fa fa-check"></i>Pathophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#recommendation"><i class="fa fa-check"></i>Recommendation</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#nsaids"><i class="fa fa-check"></i>NSAIDs</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#pathophysiology-1"><i class="fa fa-check"></i>Pathophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#recommendation-1"><i class="fa fa-check"></i>Recommendation</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#chloroquinehydroxychloroquine"><i class="fa fa-check"></i>Chloroquine/Hydroxychloroquine</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#toxicity"><i class="fa fa-check"></i>Toxicity</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#monitoring"><i class="fa fa-check"></i>Monitoring</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#azithromycin"><i class="fa fa-check"></i>Azithromycin</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#toxicity-1"><i class="fa fa-check"></i>Toxicity</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#monitoring-1"><i class="fa fa-check"></i>Monitoring</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#cardiovascular-testing-considerations"><i class="fa fa-check"></i>Cardiovascular Testing Considerations</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#deferral-of-non-urgent-testingprocedures"><i class="fa fa-check"></i>Deferral of Non-urgent Testing/Procedures</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#stress-testing-and-imaging"><i class="fa fa-check"></i>Stress Testing and Imaging</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#electrophysiology"><i class="fa fa-check"></i>Electrophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#heart-failuretransplant"><i class="fa fa-check"></i>Heart Failure/Transplant</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#interventional-cardiology"><i class="fa fa-check"></i>Interventional Cardiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#structural-heart-disease"><i class="fa fa-check"></i>Structural Heart Disease</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#cardiac-surgery"><i class="fa fa-check"></i>Cardiac Surgery</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#vascular"><i class="fa fa-check"></i>Vascular</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-clinical-reference.html"><a href="cardiovascular-clinical-reference.html#rehabilitation"><i class="fa fa-check"></i>Rehabilitation</a></li>
</ul></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="clinical-trials.html"><a href="clinical-trials.html"><i class="fa fa-check"></i>Clinical Trials</a></li>
<li class="chapter" data-level="" data-path="limited-resource-allocation.html"><a href="limited-resource-allocation.html"><i class="fa fa-check"></i>Limited Resource Allocation</a></li>
<li class="chapter" data-level="" data-path="journal-resources.html"><a href="journal-resources.html"><i class="fa fa-check"></i>Journal Resources</a></li>
<li class="chapter" data-level="" data-path="social-media-resources.html"><a href="social-media-resources.html"><i class="fa fa-check"></i>Social Media Resources</a></li>
<li class="chapter" data-level="" data-path="miscellaneous-notesresources.html"><a href="miscellaneous-notesresources.html"><i class="fa fa-check"></i>Miscellaneous Notes/Resources</a></li>
<li class="chapter" data-level="" data-path="recent-updates.html"><a href="recent-updates.html"><i class="fa fa-check"></i>Recent Updates</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">COVID-19 Resources for Penn Cardiologists</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="cardiovascular-clinical-reference" class="section level1">
<h1>Cardiovascular Clinical Reference</h1>
<div id="acute-cardiac-injury" class="section level2">
<h2>Acute Cardiac Injury</h2>
<div id="definition" class="section level3">
<h3>Definition</h3>
<p>Serum levels of cardiac biomarkers (eg, high-sensitivity cardiac troponin I) above the 99th percentile upper reference limit, or new electrocardiographic and echocardiographic abnormalities (<a href="https://pubmed.ncbi.nlm.nih.gov/31986264/">Huang, et al., Lancet, 2020</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</p>
</div>
<div id="diagnostics" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>Cardiac troponin, NT-proBNP<br />
</li>
<li>ECG<br />
</li>
<li>Consider limited echocardiogram<br />
</li>
<li>Consider measurement of inflammatory markers to evaluate hyperinflammation (Ferritin, iL-6, LDH, D-dimer)</li>
</ul>
</div>
<div id="incidence" class="section level3">
<h3>Incidence</h3>
<ul>
<li>12% overall, 31% ICU, 4% non-ICU (<a href="https://pubmed.ncbi.nlm.nih.gov/31986264/">Huang, et al., Lancet, 2020</a>)</li>
<li>17% overall (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
<li>19.7% overall (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>27.8% (n = 52) (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
</ul>
</div>
<div id="prognostic-implications" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Associated with increased utilization of noninvasive ventilation (38 [46.3%] vs 13 [3.9%]; P &lt; .001) and invasive mechanical ventilation (18 [22.0%] vs 14 [4.2%]; P &lt; .001) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>Associated with increased mortality
<ul>
<li>Occured in 59% of non-survivors (N = 32) vs. 1% of survivors (N = 1) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
<li>Adjusted HR 4.26 [95% CI, 1.92-9.49] p &lt; 0.001) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>Mortality 59.6% (n = 31) in individuals with ↑TnT vs. 8.9% (n = 12) with normal TnT; p &lt; 0.001 (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
<li>Possible interaction between underlying cardiovascular disease (CVD) and myocardial injury
<ul>
<li>Mortality 7.62% (8 of 105) among patients without CVD + normal TnT, 13.33% (4 of 30) for underlying CVD + normal TnT levels, 37.50% (6 of 16) for those without underlying CVD + ↑TnT levels, and 69.44% (25 of 36) for underlying CVD + ↑TnT (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="treatment-considerations" class="section level3">
<h3>Treatment Considerations</h3>
<ul>
<li>Supportive care</li>
<li>If associated with concomittant hyperinflammation/cytokine storm/secondary HLH, consider anti-IL6 or anti-IL1 therapy (see <a href="cardiovascular-clinical-reference.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release">Secondary Hemophagocytic Lymphohistiocytosis/Cytokine Release</a>)</li>
</ul>
</div>
</div>
<div id="acute-coronary-syndrome" class="section level2">
<h2>Acute Coronary Syndrome</h2>
<div id="definition-1" class="section level3">
<h3>Definition</h3>
<p>Acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia <a href="https://pubmed.ncbi.nlm.nih.gov/30153967">Thygesen, JACC, 2018</a></p>
</div>
<div id="incidence-1" class="section level3">
<h3>Incidence</h3>
<ul>
<li>As of 3/2020, case reports of acute coronary syndromes (ACS) (Type 1 MI) in the setting of COVID-19 have yet to be published (<a href="https://pubmed.ncbi.nlm.nih.gov/32201335">Driggin, et al., JACC, 2020</a>)</li>
<li>Severe respiratory has been identified as a risk factor for acute myocardial infarction
<ul>
<li>Incidence ratio [IR] 6.1, 95% CI 3.9-9.5 following influenza; IR 2.8, 95% CI 1.2–6.2 following non-influenza viral illness (<a href="https://pubmed.ncbi.nlm.nih.gov/29365305/">Kwong, et al., NEJM, 2018</a>)</li>
</ul></li>
</ul>
</div>
<div id="diagnostics-1" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>Cardiac troponin, NT-proBNP, lipid screen, A1c</li>
<li>ECG</li>
<li>Consider limited echocardiogram</li>
</ul>
</div>
<div id="treatment-considerations-scai-guidelines" class="section level3">
<h3>Treatment Considerations (SCAI Guidelines)</h3>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/32212409">Szerlip, et al.; Catheterization and Cardiovascular Interventions, 2020</a></p>
<div id="stemi" class="section level4">
<h4>STEMI</h4>
<ul>
<li>Primary PCI for <strong><em>high risk</em></strong> patients (anterior location, hypotension, elevated Killip class, cardiogenic shock, life-threatening, delayed presentation &gt;12 hours)</li>
<li>Consider fibrinolysis for <strong><em>low risk</em></strong> patients without contraindications (intracranial hemorrhage, prior stroke, recent trauma/surgery, intracranial malignancy/arteriovenous malformation/aneurysm, active bleeding, uncontrolled hypertension); otherwise consider primary PCI or medical management</li>
</ul>
</div>
<div id="nstemi" class="section level4">
<h4>NSTEMI</h4>
<ul>
<li>Early angiography (&lt;2 hours) for <strong><em>very high risk</em></strong> patients (refractory chest pain, heart failure, cardiogenic shock, life-threatening arrhythmia)</li>
<li>Conservative management for <strong><em>non-very high risk</em></strong> patients with antiplatelet therapy, anticoagulation (48 hours), high-intensity statin, beta-blocker, ACE-inhibitor (if indicated)</li>
</ul>
</div>
</div>
</div>
<div id="arrhythmia" class="section level2">
<h2>Arrhythmia</h2>
<div id="incidence-2" class="section level3">
<h3>Incidence</h3>
<ul>
<li>16.7% (n = 23) overall; 44% (n = 16) of patients transferred to ICU (<a href="https://pubmed.ncbi.nlm.nih.gov/32031570/">Wang, et al., JAMA, 2020</a>)</li>
<li>VT/VF in 5.9% (n = 11) (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
<li>Palpitations in 7.2% (n = 10) (<a href="https://pubmed.ncbi.nlm.nih.gov/32044814">Liu, et al., Chinese Medical Journal, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-2" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>BMP, magnesium, TSH</li>
<li>Telemetry</li>
<li>ECG</li>
<li>Consider limited echocardiogram</li>
</ul>
</div>
<div id="treatment-considerations-1" class="section level3">
<h3>Treatment Considerations</h3>
<div id="atrial-fibrillationflutter" class="section level4">
<h4>Atrial Fibrillation/Flutter</h4>
<ul>
<li>No hypotension/shock: Beta blockade and/or calcium-channel blockade</li>
<li>Hypotension/shock: Consider amiodarone infusion</li>
</ul>
</div>
<div id="ventricular-tachycardia" class="section level4">
<h4>Ventricular Tachycardia</h4>
<ul>
<li>Pulseless/Unstable: ACLS, defibrillation/cardioversion</li>
<li>Stable: Consider amiodarone or lidocaine infusion</li>
</ul>
</div>
</div>
</div>
<div id="myopericarditis" class="section level2">
<h2>Myo/Pericarditis</h2>
<div id="incidence-3" class="section level3">
<h3>Incidence</h3>
<p>Myocarditis and pericarditis may be sources of acute cardiac injury based on case reports, overall incidence unclear (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32125452">Ruan et al, Intensive Care Med, 2020</a>; <a href="http://dx.doi.org/10.20944/preprints202003.0180.v1">Zeng et al, Preprints, 2020</a>; <a href="http://www.ncbi.nlm.nih.gov/pubmed/32176300">Hu et al, Eur Heart J, 2020</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/32219357">Inciardi, et al., JAMA Cardiology 2020</a>)</p>
</div>
<div id="diagnostics-3" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>Cardiac troponin, NT-proBNP</li>
<li>ECG - case reports of pseudo-STEMI manifestations</li>
<li>Consider limited echocardiogram</li>
<li>Unclear role of endomyocardial biopsy and/or cardiac MRI</li>
</ul>
</div>
<div id="management" class="section level3">
<h3>Management</h3>
<ul>
<li>Supportive treatment; consider colchicine, NSAIDs</li>
<li>Anecdotal/case reports above describe treatment with steroids and IVIG in Wuhan</li>
</ul>
</div>
</div>
<div id="thromboembolic-diseasecoagulopathy" class="section level2">
<h2>Thromboembolic Disease/Coagulopathy</h2>
<div id="incidence-4" class="section level3">
<h3>Incidence</h3>
<ul>
<li>Mild thrombocytopenia (platelets 100-150) in 20% (n = 13) (<a href="https://pubmed.ncbi.nlm.nih.gov/32129508">Fan, et al., American Journal of Hematology, 2020</a>)</li>
<li>Coaguloapthy in 34.1% (n = 42) (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
<li>Coagulopathy (defined as 3-second extension of PT or a 5-second extension of aPTT) in 19% (n = 37) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-4" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>D-dimer, PT/INR, aPTT, fibrinogen, peripheral smear/manual differential</li>
</ul>
</div>
<div id="prognostic-implications-1" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Elevated D-dimer levels (&gt;1g/L) associated with in-hospital death (adjusted OR 18.4 95% CI 2.6-128.6, p=0.003) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)<br />
</li>
<li>Coagulopathy present in 50% (n = 27) of non-survivors vs. 7% (n = 10) in survivors (p &lt;0.001) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)<br />
</li>
<li>Disseminated intravascular coagulation present in 71.4% (n = 15) of non-survivors vs. 0.6% (n = 1) in survivors (<a href="https://pubmed.ncbi.nlm.nih.gov/32073213">Tang, et al., Journal of Thrombosis and Haemostasis, 2020</a>)</li>
</ul>
</div>
<div id="treatment-considerations-2" class="section level3">
<h3>Treatment Considerations</h3>
<ul>
<li>VTE prophylaxis</li>
<li>Possible role for empiric anticoagulation in individuals with elevated D-dimer (<a href="https://pubmed.ncbi.nlm.nih.gov/32220112">Tang, et al., Journal of Thrombosis and Haemostasis, 2020</a>)</li>
</ul>
</div>
</div>
<div id="secondary-hemophagocytic-lymphohistiocytosiscytokine-release" class="section level2">
<h2>Secondary Hemophagocytic Lymphohistiocytosis/Cytokine Release</h2>
<div id="definition-2" class="section level3">
<h3>Definition</h3>
<p>Hyperinflammatory syndrome characterised by macrophage activation, fulminant hypercytokinemia, associated with multiorgan failure and shock</p>
</div>
<div id="clinical-presentation" class="section level3">
<h3>Clinical Presentation</h3>
<p>Fever, splenomegaly, cytopenias, and hyperferritinemia, with progression to ARDS in 54% (<a href="https://pubmed.ncbi.nlm.nih.gov/26836913">Seguin, et al., Chest, 2016</a>)</p>
</div>
<div id="incidence-5" class="section level3">
<h3>Incidence</h3>
<ul>
<li>Unclear incidence/prevalence in COVID infection, although a similar pattern of dysregulated immune response has been reported (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32192578">Mehta et al, Lancet, 2020</a>)</li>
<li>Similar response identified in SARS-CoV-1 and MERS infections (<a href="http://www.ncbi.nlm.nih.gov/pubmed/27709848">Kim et al, J Korean Med Sci, 2016</a>)</li>
<li>Occurs in 3.7-4.3% of patients with sepsis (<a href="https://pubmed.ncbi.nlm.nih.gov/30766533">Karakike, et al., Frontiers in Immunology, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-5" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>CBC with differential, PT/INR, aPTT, fibrinogen, D-dimer, ferritin, hepatic function panel, triglycerides, inflammatory markers (ESR/CRP); consider NK-function, soluble IL-2 receptor in discussion with hematology/oncology</li>
<li>Calculate H-score (<a href="https://www.mdcalc.com/hscore-reactive-hemophagocytic-syndrome">MDcalc</a>)</li>
</ul>
</div>
<div id="prognostic-implications-2" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Associated with rapid progression to ARDS, shock, and multiorgan failure (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32007143">Chen et al, Lancet, 2020</a>)</li>
</ul>
</div>
<div id="treatment-considerations-3" class="section level3">
<h3>Treatment Considerations</h3>
<ul>
<li>Care typically supportive</li>
<li>Consideration of IVIG, steroids (may be associated with worsened lung injury), enrollment in clinical trial (or off-label use) of cytokine blockade (IL-6 [eg. tocilizumab, sarilumab] or IL-1 antagonists [eg. anakinra])</li>
</ul>
</div>
</div>
<div id="cardiomyopathyheart-failurecardiogenic-shock" class="section level2">
<h2>Cardiomyopathy/Heart Failure/Cardiogenic Shock</h2>
<div id="incidence-6" class="section level3">
<h3>Incidence</h3>
<ul>
<li>23% overall (n = 44) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
<li>33% (n = 7) of ICU patients in Washington State (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32191259">Arentz et al., JAMA, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-6" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>Physical Exam: ↑JVP/CVP, edema, rales/crackles
<ul>
<li>Pulse pressure &lt; 25% of SBP correlates highly with cardiac index &lt; 2.2 (sensitivity 91%, specificity 83%) (<a href="http://www.ncbi.nlm.nih.gov/pubmed/2913385">Stevenson and Perloff, JAMA, 1989</a>)</li>
</ul></li>
<li>Labs: Cardiac troponin, NT-proBNP, lactate, central/mixed venous oxygen saturation (ScVO2) if available</li>
<li>ECG</li>
<li>Chest x-ray</li>
<li>Consider limited echocardiogram</li>
</ul>
</div>
<div id="prognostic-implications-3" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Chronic heart failure associated with increased risk of acute cardiac injury (14.6% vs. 1.5%) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>Associated with increased risk of mortality, more common in non-survivors (52%, n = 28) vs. survivors (12%, n = 16) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
</ul>
</div>
<div id="management-1" class="section level3">
<h3>Management</h3>
<div id="stablechronic" class="section level4">
<h4>Stable/Chronic</h4>
<ul>
<li>Goal-directed medical therapy with beta-blockade, ACE/ARB/ARNI, mineralocorticoid receptor antagonist</li>
<li><a href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang">ESC</a> and <a href="https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp">HFSA/ACC/AHA</a> recommend continuation of ACE/ARB/ARNI. See <a href="cardiovascular-clinical-reference.html#medication-considerations">Medication Considerations</a></li>
</ul>
</div>
<div id="unstablecardiogenic-shock" class="section level4">
<h4>Unstable/Cardiogenic Shock</h4>
<ul>
<li>Consider invasive hemodynamic monitoring with arterial and central venous catheters</li>
<li>Goals: MAPs 65-75, CVP 6-14, PCWP 12-18, PAD 20-25, SVR 800-1000, SCvO2 &gt; 60%, CI &gt; 2.2 (Note: Achieving MAP goal is first priority, then optimize other parameters)</li>
<li>Ensure negative inotropes such as beta blockers, calcium channel blockers and antihypertensives are discontinued.</li>
<li>Titration of norepinephrine infusion for goal MAP 65-75</li>
<li>Initiate diuretic therapy for CVP &gt; 14, PCWP &gt;18, PAD &gt; 25</li>
<li>Consider inotropic support (eg. dobutamine or epinephrine infusions)</li>
</ul>
</div>
</div>
</div>
<div id="medication-considerations" class="section level2">
<h2>Medication Considerations</h2>
<div id="acearbarni" class="section level3">
<h3>ACE/ARB/ARNI</h3>
<div id="pathophysiology" class="section level4">
<h4>Pathophysiology</h4>
<ul>
<li>Angiotensin converting enzyme 2 (ACE2) serves as the entry point for SARS-CoV-2 into human cells. In animal models, both angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been shown to upregulate ACE2 expression in the heart, raising concern that these medications may increase susceptibility to COVID-19. (<a href="https://pubmed.ncbi.nlm.nih.gov/32208485">Patel et al., JAMA 2020</a>)</li>
<li>There is no clinical evidence that ACE/ARB/ARNI are associated with increased risk of COVID-19.</li>
<li>Preclinical models have suggested ARBs may attenuate SARS-CoV-induced lung injury (<a href="https://pubmed.ncbi.nlm.nih.gov/16007097/">Kuba, et al., Nature Medicine, 2005</a>)</li>
</ul>
</div>
<div id="recommendation" class="section level4">
<h4>Recommendation</h4>
<ul>
<li><a href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang">ESC</a> and <a href="https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp">HFSA/ACC/AHA</a> recommend continuation of ACE/ARB/ARNI.</li>
</ul>
</div>
</div>
<div id="nsaids" class="section level3">
<h3>NSAIDs</h3>
<div id="pathophysiology-1" class="section level4">
<h4>Pathophysiology</h4>
<ul>
<li>NSAIDs suppress prostaglandin synthases 1 and 2 (COX-1 and COX-2), enzymes responsible for producing prostaglandins (lipids which can trigger pain and fever)</li>
<li>SARS-CoV-1 binds to the COX-2 promotor, increasing expression of this enzyme (<a href="https://science.sciencemag.org/lookup/external-ref?access_num=16546436&amp;link_type=MED&amp;atom=%2Fsci%2F367%2F6485%2F1434.1.atom">Yan, et al., Int. J. Biochem. Cell Biol., 2006</a>)
<ul>
<li>PGE2 may inhibit coronavirus replication (<a href="https://science.sciencemag.org/lookup/external-ref?access_num=17302372&amp;link_type=MED&amp;atom=%2Fsci%2F367%2F6485%2F1434.1.atom">Amici et al., Antivir. Ther., 2006</a>)</li>
</ul></li>
<li>Indomethacin may block coronavirus RNA synthesis independent of COX inhibition (<a href="https://science.sciencemag.org/lookup/external-ref?access_num=28261111&amp;link_type=MED&amp;atom=%2Fsci%2F367%2F6485%2F1434.1.atom">Sander et al., Front. Physiol, 2017</a>)</li>
<li><strong>Overall:</strong> NSAIDs and the cyclooxygnase pathway have been implicated mechanistically in both increased and decreased susceptibility to SARS-CoV</li>
</ul>
</div>
<div id="recommendation-1" class="section level4">
<h4>Recommendation</h4>
<ul>
<li>There is no strong clinical evidence <em>for</em> or <em>against</em> the use of NSAIDs in individuals with (or at-risk-of) SARS-CoV-2 infection (<a href="https://pubmed.ncbi.nlm.nih.gov/32198292">Fitzgerald, Science, 2020</a>)</li>
</ul>
</div>
</div>
<div id="chloroquinehydroxychloroquine" class="section level3">
<h3>Chloroquine/Hydroxychloroquine</h3>
<div id="toxicity" class="section level4">
<h4>Toxicity</h4>
<ul>
<li><strong>Cardiovascular:</strong> Atrioventricular block, bundle branch block, cardiac arrhythmia, cardiomyopathy, ECG changes (including prolonged QRS and QTc intervals, T-wave inversion, or depression), hypotension, torsades de pointes, ventricular fibrillation, ventricular tachycardia (<a href="https://www.uptodate.com/contents/chloroquine-drug-information?sectionName=Adult&amp;topicId=9247&amp;search=chloroquine&amp;usage_type=panel&amp;anchor=F149786&amp;source=panel_search_result&amp;selectedTitle=1~114&amp;kp_tab=drug_general&amp;display_rank=1#F3195083">UpToDate</a>)</li>
<li><strong>Ophthalmologic:</strong> toxicity is uncommon with short-term use; long-term use associated with retinal toxicity</li>
</ul>
</div>
<div id="monitoring" class="section level4">
<h4>Monitoring</h4>
<ul>
<li>ECG (baseline QTc)</li>
<li>Consider telemetry</li>
</ul>
</div>
</div>
<div id="azithromycin" class="section level3">
<h3>Azithromycin</h3>
<div id="toxicity-1" class="section level4">
<h4>Toxicity</h4>
<ul>
<li><strong>Altered cardiac conduction:</strong> QTc prolongation, ventricular arrhythmias, torsades de pointes; consider avoiding use in patients with prolonged QT interval, congenital long QT syndrome, history of torsades de pointes, bradyarrhythmias, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, uncompensated heart failure, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents or other drugs known to prolong the QT interval. (<a href="https://www.uptodate.com/contents/azithromycin-systemic-drug-information?search=azithromycin&amp;source=panel_search_result&amp;selectedTitle=1~146&amp;usage_type=panel&amp;display_rank=1#F7983222">UpToDate</a>)</li>
</ul>
</div>
<div id="monitoring-1" class="section level4">
<h4>Monitoring</h4>
<ul>
<li>ECG (baseline QTc)</li>
<li>Consider telemetry</li>
</ul>
</div>
</div>
</div>
<div id="cardiovascular-testing-considerations" class="section level2">
<h2>Cardiovascular Testing Considerations</h2>
<div id="deferral-of-non-urgent-testingprocedures" class="section level3">
<h3>Deferral of Non-urgent Testing/Procedures</h3>
<p>This section provides guidance from the <a href="https://www.acc.org/latest-in-cardiology/articles/2020/03/24/09/42/general-guidance-on-deferring-non-urgent-cv-testing-and-procedures-during-the-covid-19-pandemic">ACC</a> regarding non-urgent cardiovascular testing and procedures that may be deferred, by specialty.</p>
<div id="stress-testing-and-imaging" class="section level4">
<h4>Stress Testing and Imaging</h4>
<ul>
<li>Stress testing (ECG alone or with imaging [echocardiography, radionuclide, MRI]) for suspected stable ischemic heart disease (outpatient and inpatient)</li>
<li>Cardiopulmonary exercise testing for functional assessment (outpatient and inpatient)</li>
<li>Transthoracic echocardiograms (outpatient)</li>
<li>Transesophageal echocardiograms in stable patients (outpatient and inpatient)</li>
<li>Cardiovascular computed tomography (CT) (outpatient)</li>
<li>Cardiovascular magnetic resonance imaging (MRI) (outpatient)</li>
<li>Nuclear cardiac imaging (SPECT and PET) (outpatient and inpatient)</li>
<li>Vascular imaging for asymptomatic carotid artery disease (outpatient and inpatient)</li>
<li>Vascular imaging for claudication (outpatient and inpatient)</li>
<li>Imaging for screening purposes (e.g., coronary calcium score, screening ultrasound to assess for an AAA) (outpatient and inpatient)</li>
</ul>
</div>
<div id="electrophysiology" class="section level4">
<h4>Electrophysiology</h4>
<ul>
<li>In-person cardiovascular implantable electronic device (CIED) checks/interrogations (outpatient) and absent new cardiovascular symptoms (inpatient)</li>
<li>Cardioversions in stable, asymptomatic patients (outpatient and inpatient)</li>
<li>Tilt table test (outpatient and inpatient)</li>
<li>Implantable loop recorder (ILR) implant absent cryptogenic stroke (outpatient and inpatient)</li>
<li>Pacemaker implant for stable sinus node dysfunction or second-degree AV block without syncope (outpatient and inpatient)</li>
<li>ICD placement for primary prevention in stable, low-risk patients (outpatient)</li>
<li>Upgrade to cardiac resynchronization therapy (CRT) in stable patients (outpatient and inpatient)</li>
<li>Atrial fibrillation ablation in stable patients (e.g., without refractory heart failure) (outpatient and inpatient)</li>
<li>Atrial flutter ablation in stable patients (e.g., without refractory heart failure) (outpatient and inpatient)</li>
<li>SVT ablation in stable patients (outpatient and inpatient)</li>
<li>PVC ablation in stable patients (outpatient and inpatient)</li>
<li>Left atrial appendage closure/occlusion (e.g., Watchman) (outpatient and inpatient)</li>
<li>Lead extraction unrelated to infection or symptomatic lead failure (outpatient and inpatient)</li>
</ul>
</div>
<div id="heart-failuretransplant" class="section level4">
<h4>Heart Failure/Transplant</h4>
<ul>
<li>Cardiopulmonary exercise testing for functional assessment (outpatient and inpatient)</li>
<li>Right heart catheterization (outpatient)</li>
<li>Surveillance right heart catheterization and cardiac biopsy post cardiac transplant (outpatient)</li>
<li>Surveillance coronary angiography post cardiac transplant (outpatient)</li>
<li>Hemodynamic monitor implant (e.g. CardioMEMS) (outpatient and inpatient)</li>
</ul>
</div>
<div id="interventional-cardiology" class="section level4">
<h4>Interventional Cardiology</h4>
<ul>
<li>Coronary angiography ± intervention for stable ischemic heart disease (outpatient and inpatient)</li>
<li>Coronary angiography ± intervention for non-cardiac preoperative evaluation (outpatient and inpatient)</li>
<li>Chronic total occlusion (CTO) intervention (outpatient and inpatient)</li>
<li>Coronary brachytherapy (outpatient and inpatient)</li>
<li>Surveillance coronary angiography post cardiac transplant (outpatient)</li>
<li>Right heart catheterization (outpatient)</li>
<li>Pulmonary angiography (outpatient)</li>
<li>Balloon pulmonary angioplasty for CTEPH (outpatient and inpatient)</li>
<li>Renal angiography ± intervention (outpatient and inpatient)</li>
</ul>
</div>
<div id="structural-heart-disease" class="section level4">
<h4>Structural Heart Disease</h4>
<ul>
<li>PFO/ASD closure (outpatient and inpatient)</li>
<li>Transcatheter aortic valve replacement (TAVR) in asymptomatic patients (outpatient and inpatient)</li>
<li>Percutaneous mitral valve repair (e.g., MitraClip) or replacement (e.g., valve-in-valve) (outpatient)</li>
<li>Left atrial appendage closure/occlusion (e.g., Watchman) (outpatient and inpatient)</li>
</ul>
<ol start="20" style="list-style-type: lower-alpha">
<li></li>
</ol>
</div>
<div id="cardiac-surgery" class="section level4">
<h4>Cardiac Surgery</h4>
<ul>
<li>Coronary artery bypass graft (CABG) surgery for stable ischemic heart disease (outpatient and inpatient)</li>
<li>Valve repair/replacement in asymptomatic patients (outpatient and inpatient)</li>
<li>Repair of asymptomatic ascending aortic aneurysm (&lt;5.5 cm) among those without additional risk factors (e.g., family history) (outpatient and inpatient)</li>
<li>Surgical treatment of atrial fibrillation (including convergent procedure) (outpatient)</li>
</ul>
</div>
<div id="vascular" class="section level4">
<h4>Vascular</h4>
<ul>
<li>Upper extremity angiography ± intervention (outpatient and inpatient)</li>
<li>Lower extremity angiography ± intervention for claudication (outpatient and inpatient)</li>
<li>Lower extremity surgical revascularization for claudication (outpatient and inpatient)</li>
<li>Lower extremity angiography ± intervention for non-healing wounds (without impending limb/tissue loss) (outpatient and inpatient)</li>
<li>Lower extremity surgical revascularization for non-healing wounds (without impending limb/tissue loss) (outpatient and inpatient)</li>
<li>Carotid angiography ± intervention in asymptomatic patients (outpatient and inpatient)</li>
<li>Transcarotid artery revascularization (TCAR) or other surgical revascularization in asymptomatic patients (outpatient and inpatient)</li>
<li>Renal angiography ± intervention (outpatient and inpatient)</li>
<li>Creation of dialysis access (AV fistula) (outpatient)</li>
<li>Repair of asymptomatic ascending aortic aneurysm (&lt;5.5 cm) among those without additional risk factors (e.g., family history) (outpatient and inpatient)</li>
<li>Endovascular or open treatment of an unruptured abdominal aortic aneurysm (AAA) ≤5.5 cm (outpatient and inpatient)</li>
<li>Endovascular or open treatment of an unruptured thoracic aortic aneurysm (AAA) ≤5.5 cm (outpatient and inpatient)</li>
<li>Venous ablation (outpatient and inpatient)</li>
<li>Venous stenting (outpatient and inpatient)</li>
</ul>
</div>
<div id="rehabilitation" class="section level4">
<h4>Rehabilitation</h4>
<ul>
<li>Cardiac rehabilitation, phase 1 (inpatient) and 2/3 (outpatient)</li>
<li>Pulmonary rehabilitation (outpatient)</li>
<li>Vascular rehabilitation (outpatient)</li>
</ul>
</div>
</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="major-cardiovascular-society-resources.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="clinical-trials.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": true,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"all": ["facebook", "twitter"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
